Trending...
- Sootheez Revolutionizes Relaxation: A New Era of Therapeutic Comfort Unveiled
- Wave2 Launches New Dynamic Data Integration Features to Elevate Bank and Credit Union Convenience
- Metro Commercial Miami Team Doubles
* HMBD ~ Hummingbird Bioscience, a data-driven precision biotherapeutics company, announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will summarize the Phase 1 clinical trial design for HMBD-002.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
- The Signature Room at the John Hancock Tower Announces Unexpected Closure
- Global Luxury Value Exchange, Idoneus, Transitions to 100% IDON Transactions
- USA Green Card Celebrates the State Department's Historic Inclusion of the UK in the DV-2025 Green Card Lottery
- Brighter Smile Just Launched Their New Website!
- Windy City Implant And Dental Centers Just Launched Their New Website!
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Updated Version 9 ezCheckPrinting Software Has No Validation Fees, Yearly Cost or Hidden Costs
- Cleveland Broadband Selects Axiros' AXESS 5 ACS Software for Advanced Gigabit Internet Service
- Naperville: Pre-Trial Detention Ordered for Chicago Convicted Felon on Parole Charged with Armed Habitual Criminal for Alleged Illegal Possession of a Firearm
- Chicago Public Schools Announces Stabilized Enrollment after Years of Decline
- Green Office Partner Ranks on the Inc. 5000 Annual List of the Fastest Growing Companies in America
- Office Calgary Inc, announces office expansion plans
- Chief Larry Snelling Confirmed By City Council As Chicago Police Department Superintendent
- Benefits Of Using Silicone Gel Socks
- Fireandaxes.Com Unveils Original Firefighter Coins and Engravable Firefighting Coins
- Collinwood Earns Certified Veteran's Business Enterprise™ Designation from the National Veteran Owned Business Association (NaVOBA)
- Microsoft and Mercy collaborate to empower clinicians to transform patient care with generative AI
- PFW Recap: CHOCHENG Spring/Summer 2024 Les Parapluies De CHOCHENG
- The New Trace One Ushers in a New Era for CPG and Retail Product Innovation
- Quill Continues to Grow Nationwide Footprint with Sizeable New Partnerships Spanning Businesses Across Multiple Industries
- Freightos' WebCargo Partners with Chapman Freeborn to Offer Extensive Global Capacity
- Breaking the Mold: The Human Conditioning Dilemma with Radavie
- Naperville: Structure Fire in the 4100 Block of Emporia Ct.
- Aquasight Unveils Aquasight Copilot™ to Aid & Assist Water and Wastewater Utilities
- Youth Employment Up 19 Percent From 2022 Through One Summer Chicago
- The Luxe Team at Dale Sorensen Real Estate Brevard Presents 100 Ocean Condominium in Melbourne, Florida